Roll-over Study to Allow Continued Access to Ribociclib

Key inclusion Criteria:

1. Currently participating in a Novartis sponsored global study (parent study),receiving treatment with ribociclib in combination with other drugs, and the parentstudy has fulfilled its primary objective(s)

2. Must have been receiving treatment with ribociclib for at least 6 cycles in theparent study

3. Currently has evidence of clinical benefit as determined by the Investigator

Key exclusion Criteria:

1. Permanent discontinuation of ribociclib in the parent study

2. Currently has unresolved toxicities for which ribociclib dosing has been interruptedin the parent study 3. Local access to commercially available ribociclib andreimbursed

Other protocol-defined inclusion/exclusion criteria may apply at the end